Effect of addition of pemafibrate and double dose of statin on small dense LDL cholesterol in statin-treated patients with type 2 diabetes and hypertriglyceridemia: A comparative Study. - PRESTIGE

Mori Yusaku0 个研究点目标入组 102 人开始时间: 2020年2月28日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1. Age>=20 years old
•2. Type 2 diabetes patients
•3. Patients who have been taking below statins for 3 months or longer without changing
•Atorvastatin 5, 10 mg/day
•Pitavastatin 1, 2 mg/day
•Rosuvastatin 2.5 mg/day
•4. 150mg/dL=5. Written informed consent

•1. Type 1 diabetes patients
•2. 160mg/dL=3. Patients taking cyclosporine, rifampicin, PCSK9 inhibitors, MTP inhibitors
•4. HbA1c>=10% within three months prior to informed consent
•5. familial hypercholesteremia
•6. Patients taking statins other than those specified in the inclusion criteria
•7. Patients taking statins other than those prescribed by the inclusion criteria
•8. Patients who have taken SPPARM alpha or fibrates within three months prior to informed consent
•9. Patients who have changed prescriptions for dyslipidemia * and diabetes <*Ezetimibe (including compounding agents), anion exchange resin, ethyl icosapentate (including supplements), ethyl omega-3 fatty acid (including supplements)> within three months prior to informed consent
•10. Patients receiving pemafibrate
•11. 1.5mg/dL=12. Alcoholics patients (or alcohol abuse patients)
•13. Patients who have developed diabetic ketoacidosis within three months prior to informed consent
•14. Patients with active malignant tumor, autoimmune disease, infectious disease
•15. Any other patients regarded unsuitable by the principal investigator or sub-investigators

发起方

Mori Yusaku